ArticleProstate cancer and prostatic diseases2026
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy.
Zuomin Wang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.